P-glycoprotein, an active transporter that pumps a diverse range of hydrophobic compounds out of cells, has recently been proposed to function as, or regulate, a volume-activated, anion-selective channel (Valverde, M.A., Diaz, M., Sepulveda, F. V., Gill, D. R., Hyde, S. C., and Higgins, C. F. (1992) Nature 355, 830-833). In this study a number of compounds known to inhibit P-glycoprotein-mediated drug pumping were tested for their effect on the osmotically activated release from HeLa cells of I-, a known substrate of volume-activated anion channels, and taurine, a sulfonic amino acid that serves as an important organic osmolyte in many cell-types. Tamoxifen, 4-iodotamoxifen, and pyrrolidino-4-iodotamoxifen (idoxifene) were potent blockers of osmotically activated I- and taurine efflux. Other known P-glycoprotein inhibitors (verapamil, cyclosporin A, pimozide, trifluoperazine, ICI 164, and ICI 182) were less effective. For all compounds tested the effect on taurine release was the same as that on I- release, consistent with the hypothesis that swelling-activated taurine release is via anion-selective channels. There was no positive correlation between the effect of the inhibitors on osmotically activated solute release and their effect on P-glycoprotein-mediated drug transport. In contrast, there was a strong positive correlation between the IC50 values for the effect of the inhibitors on volume-activated solute release and those for their effect on calmodulin. These data raise doubts as to whether the effect of P-glycoprotein inhibitors on volume-activated channels is a consequence of their interaction with P-glycoprotein and indicate a possible role for calmodulin, or a cell component having at least some physical similarities, in controlling channel activity.
No takes yet. Share an insight, caveat, or question.
Kirk et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: